title: [Hodgkin and non-Hodgkin lymphoma of adolescents and young adults].
abstract: Lymphoma is one of the most frequent cancers in adolescent and young adults. Hodgkin Lymphoma is curable in more than 90% of cases. Recent pediatric and adults protocols aimed to decrease long term toxicities (mostly gonadic and cardiovascular) and secondary malignancies, reducing the use of alkylating agents and limiting radiation fields. Risk-adapted strategies, using positron emission tomography staging, are about to become a standard, both in adult and pediatric protocols. These approaches allow obtaining excellent results in adolescents with Hodgkin lymphoma. On the other hand, treatment of adolescents with diffuse large B-cell lymphoma raises some questions. Even through children have good outcomes when treated with risk-adapted strategies, adolescents who are between 15 and 18 years old seem to experience poorer survivals, whereas patients older than 18 years old have globally the same outcome than older adults. This category of patient needs a particular care, based on a tight coordination between adults and pediatric oncologists. Primary mediastinal lymphomas, a subtype of BLDCL frequent in young adult population, exhibits poorer outcomes in children or young adolescent population than in older ones. Taking together, B-cell lymphoma benefited from recent advances in immunotherapy (in particular with the extended utilization of rituximab) and metabolic response-adapted strategies. In conclusion, adolescent and young adult's lymphomas are very curable diseases but require a personalized management in onco-hematological units.
authors.affiliation: Institut Paoli-Calmettes, département d'hématologie, 232, boulevard Sainte-Marguerite, 13009 Marseille, France. Electronic address: garciazs@ipc.unicancer.fr.
authors.forename: Sylvain
authors.initials: S
authors.lastname: Garciaz
authors.affiliation: Institut Paoli-Calmettes, département d'hématologie, 232, boulevard Sainte-Marguerite, 13009 Marseille, France.
authors.forename: Diane
authors.initials: D
authors.lastname: Coso
authors.affiliation: Hôpital Saint-Louis, service d'hémato-oncologie, 1, avenue Claude-Vellefaux, 75010 Paris, France.
authors.forename: Pauline
authors.initials: P
authors.lastname: Brice
authors.affiliation: Institut Paoli-Calmettes, département d'hématologie, 232, boulevard Sainte-Marguerite, 13009 Marseille, France.
authors.forename: Réda
authors.initials: R
authors.lastname: Bouabdallah
mesh_terms: D000293:Adolescent; D000367:Age Factors; D000970:Antineoplastic Agents / Q000627:therapeutic use; D006689:Hodgkin Disease / Q000401:mortality / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy; D016403:Lymphoma, Large B-Cell, Diffuse / Q000401:mortality / Q000628:therapy; D008228:Lymphoma, Non-Hodgkin / Q000401:mortality / Q000628:therapy*; D008479:Mediastinal Neoplasms / Q000401:mortality / Q000628:therapy; D011379:Prognosis; D000069283:Rituximab / Q000627:therapeutic use; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D000069283:Rituximab
keywords: Diffuse large B-cell lymphoma; Hodgkin lymphoma; Lymphome B diffus à grandes cellules; Lymphome d’Hodgkin; Lymphome primitif du médiastin; Primary mediastinal lymphoma